1.Treatment Efficacy of Various Maneuvers for Lateral Canal Benign Paroxysmal Positional Vertigo With Apogeotropic Nystagmus: A Randomized Controlled Trial
Hyun Jin LEE ; Eun-Ju JEON ; Sungil NAM ; Seog-Kyun MUN ; Shin-Young YOO ; Seong Hyun BU ; Jin Woong CHOI ; Jae Ho CHUNG ; Seok Min HONG ; Seung-Hwan LEE ; Min-Beom KIM ; Ja-Won KOO ; Hyun Ji KIM ; Jae-Hyun SEO ; Seong-Ki AHN ; Shi Nae PARK ; Minbum KIM ; Won-Ho CHUNG
Clinical and Experimental Otorhinolaryngology 2023;16(3):251-258
Objectives:
The aim of this study was to determine the most effective treatment approach by comparing the impacts of various otolith reduction techniques in patients with apogeotropic lateral semicircular canal benign paroxysmal positional vertigo (LC-BPPV).
Methods:
We performed a multicenter randomized prospective study from January to December 2015, involving 72 consecutive patients with apogeotropic LC-BPPV. The patients were divided into three treatment groups: therapeutic head-shaking (group A), the Gufoni-Appiani maneuver (group B), and the cupulolith repositioning maneuver (CuRM; group C). Each group underwent evaluation and treatment up to the fourth week. Treatment success was defined as the disappearance of positional vertigo and nystagmus.
Results:
This study included 72 patients (49 male and 23 female), with a mean (±standard deviation) age of 55.4±13.5 years. The mean duration of vertigo experienced prior to treatment was 3.9±4.4 days. The mean latency and duration of nystagmus were 2.7±3.0 seconds and 47.9±15.8 seconds, respectively. The overall treatment frequency was 2.0±0.9. The number of treatments differed significantly among the three groups (P<0.05). After 4 weeks, the success rates for groups A, B, and C were 90.5%, 92.3%, and 100%, respectively. No significant difference was observed in the success rate across treatment methods and periods (P>0.05). However, CuRM was the only method with a 100% treatment success rate.
Conclusion
While no clear difference was observed among the three treatments for LC-BPPV, CuRM was found to be superior to the other approaches in the long term.
2.Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea
Jin Seok KIM ; Jun Ho JANG ; Deog-Yeon JO ; Seo-Yeon AHN ; Sung-Soo YOON ; Je-Hwan LEE ; Sung-Hyun KIM ; Chul Won CHOI ; Ho-Jin SHIN ; Min-Kyoung KIM ; Jae Hoon LEE ; Yeung-Chul MUN ; Jee Hyun KONG ; BokJin HYUN ; HyunSun NAM ; Eunhye KIM ; Min Joo KWAK ; Yong Kyun WON ; Jong Wook LEE
Journal of Korean Medical Science 2023;38(41):e328-
Background:
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder characterized by uncontrolled terminal complement activation. Eculizumab, a monoclonal antibody C5 inhibitor was introduced in Korea in 2009 and has been the standard treatment option for PNH.
Methods:
This study assessed the long-term efficacy/safety of eculizumab in PNH using real-world data from the Korean Health Insurance Review and Assessment Service. Eighty patients who initiated eculizumab from 2009–2020 were enrolled.
Results:
At eculizumab initiation, the median age was 51.5 years, lactate dehydrogenase (LDH) 6.8 × upper limit of normal, and granulocyte clone size 93.0%. All patients had at least one PNH-related complication before eculizumab initiation, including renal failure (n = 36), smooth muscle spasm (n = 24), thromboembolism (n = 20), and pulmonary hypertension (n = 15). The median (range) duration of eculizumab treatment was 52.7 (1.0, 127.3) months (338.6 total treated patient-years). Despite high disease activity in the study population before treatment initiation, overall survival was 96.2% and LDH levels were stabilized in most patients during treatment. PNH-related complications at treatment initiation were resolved in 44.4% of patients with renal failure, 95.8% with smooth muscle spasm, 70.0% with thromboembolism, and 26.7% with pulmonary hypertension. Extravascular hemolysis occurred in 28.8% of patients (n = 23; 0.09 per patient-year) and breakthrough hemolysis in 18.8% (n = 15; 0.06 per patient-year). No treatment discontinuation cases related to eculizumab were observed.
Conclusion
These data provided evidence for the long-term efficacy and safety of eculizumab in Korean PNH patients with high disease burdens.
3.Updated recommendations for the treatment of venous thromboembolism
Junshik HONG ; Seo-Yeon AHN ; Yoo Jin LEE ; Ji Hyun LEE ; Jung Woo HAN ; Kyoung Ha KIM ; Ho-Young YHIM ; Seung-Hyun NAM ; Hee-Jin KIM ; Jaewoo SONG ; Sung-Hyun KIM ; Soo-Mee BANG ; Jin Seok KIM ; Yeung-Chul MUN ; Sung Hwa BAE ; Hyun Kyung KIM ; Seongsoo JANG ; Rojin PARK ; Hyoung Soo CHOI ; Inho KIM ; Doyeun OH ; On behalf of the Korean Society of Hematology Thrombosis and Hemostasis Working Party
Blood Research 2021;56(1):6-16
Venous thromboembolism (VTE), which includes pulmonary embolism and deep vein thrombosis, is a condition characterized by abnormal blood clot formation in the pulmonary arteries and the deep venous vasculature. It is often serious and sometimes even fatal if not promptly and appropriately treated. Moreover, the later consequences of VTE may result in reduced quality of life. The treatment of VTE depends on various factors, including the type, cause, and patient comorbidities. Furthermore, bleeding may occur as a side effect of VTE treatment. Thus, it is necessary to carefully weigh the benefits versus the risks of VTE treatment and to actively monitor patients undergoing treatment. Asian populations are known to have lower VTE incidences than Western populations, but recent studies have shown an increase in the incidence of VTE in Asia. A variety of treatment options are currently available owing to the introduction of direct oral anticoagulants.The current VTE treatment recommendation is based on evidence from previous studies, but it should be applied with careful consideration of the racial, genetic, and social characteristics in the Korean population.
4.A Deep Learning Model with High Standalone Performance for Diagnosis of Unruptured Intracranial Aneurysm
Bio JOO ; Hyun Seok CHOI ; Sung Soo AHN ; Jihoon CHA ; So Yeon WON ; Beomseok SOHN ; Hwiyoung KIM ; Kyunghwa HAN ; Hwa Pyung KIM ; Jong Mun CHOI ; Sang Min LEE ; Tae Gyu KIM ; Seung-Koo LEE
Yonsei Medical Journal 2021;62(11):1052-1061
Purpose:
This study aimed to investigate whether a deep learning model for automated detection of unruptured intracranial aneurysms on time-of-flight (TOF) magnetic resonance angiography (MRA) can achieve a target diagnostic performance comparable to that of human radiologists for approval from the Korean Ministry of Food and Drug Safety as an artificial intelligence-applied software.
Materials and Methods:
In this single-center, retrospective, confirmatory clinical trial, the diagnostic performance of the model was evaluated in a predetermined test set. After sample size estimation, the test set consisted of 135 aneurysm-containing examinations with 168 intracranial aneurysms and 197 aneurysm-free examinations. The target sensitivity and specificity were set as 87% and 92%, respectively. The patient-wise sensitivity and specificity of the model were analyzed. Moreover, the lesion-wise sensitivity and false-positive detection rate per case were also investigated.
Results:
The sensitivity and specificity of the model were 91.11% [95% confidence interval (CI): 84.99, 95.32] and 93.91% (95% CI:89.60, 96.81), respectively, which met the target performance values. The lesion-wise sensitivity was 92.26%. The overall falsepositive detection rate per case was 0.123. Of the 168 aneurysms, 13 aneurysms from 12 examinations were missed by the model.
Conclusion
The present deep learning model for automated detection of unruptured intracranial aneurysms on TOF MRA achieved the target diagnostic performance comparable to that of human radiologists. With high standalone performance, this model may be useful for accurate and efficient diagnosis of intracranial aneurysm.
5.A Deep Learning Model with High Standalone Performance for Diagnosis of Unruptured Intracranial Aneurysm
Bio JOO ; Hyun Seok CHOI ; Sung Soo AHN ; Jihoon CHA ; So Yeon WON ; Beomseok SOHN ; Hwiyoung KIM ; Kyunghwa HAN ; Hwa Pyung KIM ; Jong Mun CHOI ; Sang Min LEE ; Tae Gyu KIM ; Seung-Koo LEE
Yonsei Medical Journal 2021;62(11):1052-1061
Purpose:
This study aimed to investigate whether a deep learning model for automated detection of unruptured intracranial aneurysms on time-of-flight (TOF) magnetic resonance angiography (MRA) can achieve a target diagnostic performance comparable to that of human radiologists for approval from the Korean Ministry of Food and Drug Safety as an artificial intelligence-applied software.
Materials and Methods:
In this single-center, retrospective, confirmatory clinical trial, the diagnostic performance of the model was evaluated in a predetermined test set. After sample size estimation, the test set consisted of 135 aneurysm-containing examinations with 168 intracranial aneurysms and 197 aneurysm-free examinations. The target sensitivity and specificity were set as 87% and 92%, respectively. The patient-wise sensitivity and specificity of the model were analyzed. Moreover, the lesion-wise sensitivity and false-positive detection rate per case were also investigated.
Results:
The sensitivity and specificity of the model were 91.11% [95% confidence interval (CI): 84.99, 95.32] and 93.91% (95% CI:89.60, 96.81), respectively, which met the target performance values. The lesion-wise sensitivity was 92.26%. The overall falsepositive detection rate per case was 0.123. Of the 168 aneurysms, 13 aneurysms from 12 examinations were missed by the model.
Conclusion
The present deep learning model for automated detection of unruptured intracranial aneurysms on TOF MRA achieved the target diagnostic performance comparable to that of human radiologists. With high standalone performance, this model may be useful for accurate and efficient diagnosis of intracranial aneurysm.
6.Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis.
Junshik HONG ; Seok Jin KIM ; Jae Sook AHN ; Moo Kon SONG ; Yu Ri KIM ; Ho Sup LEE ; Ho Young YHIM ; Dok Hyun YOON ; Min Kyoung KIM ; Sung Yong OH ; Yong PARK ; Yeung Chul MUN ; Young Rok DO ; Hun Mo RYOO ; Je Jung LEE ; Jae Hoon LEE ; Won Seog KIM ; Cheolwon SUH
Cancer Research and Treatment 2015;47(2):173-181
PURPOSE: This study was conducted to evaluate outcomes in adult patients with Burkitt lymphoma (BL) or Burkitt-like lymphoma treated with an rituximab plus hyper-CVAD (R-hyper-CVAD) regimen by focusing on tolerability and actual delivered relative dose intensity (RDI). MATERIALS AND METHODS: Patients > or = 20 years of age and pathologically diagnosed with BL or Burkitt-like lymphoma were treated with at least one cycle of R-hyper-CVAD as the first-line treatment in this study. Eligible patients' case report forms were requested from their physicians to obtain clinical and laboratory data for this retrospective study. RESULTS: Forty-three patients (median age, 51 years) from 14 medical centers in Korea were analyzed, none of which were infected with human immunodeficiency virus. The majority of patients had advanced diseases, and 24 patients achieved a complete response (75.0%). After a median follow-up period of 20.0 months, 2-year event-free and overall survival rates were 70.9% and 81.4%, respectively. Eleven patients (25.6%) were unable to complete the R-hyper-CVAD regimen, including six patients due to early death. The RDIs of adriamycin, vincristine, methotrexate, and cytarabine were between 60% and 65%, which means less than 25% of patients received greater than 80% of the planned dose of each drug. Poor performance status was related to the lower RDIs of doxorubicin and methotrexate. CONCLUSION: R-hyper-CVAD showed excellent treatment outcomes in patients who were suitable for dose-intense chemotherapy. However, management of patients who are intolerant to a dose-intense regimen remains problematic due to the frequent occurrence of treatmentrelated complications.
Adult
;
Burkitt Lymphoma
;
Cytarabine
;
Doxorubicin
;
Drug Therapy
;
Follow-Up Studies
;
HIV
;
Humans
;
Korea
;
Lymphoma*
;
Methotrexate
;
Retrospective Studies
;
Survival Rate
;
Vincristine
7.Multicenter Study on the Clinician's Diagnostic and Therapeutic Approaches for Benign Paroxysmal Positional Vertigo in Korea
Eun Ju JEON ; Won Ho CHUNG ; Jeong Hwan CHOI ; Eui Cheol NAM ; Hong Ju PARK ; Jong Dae LEE ; Won Sang LEE ; Kyu Sung KIM ; Eui Kyung GOH ; Ja Won KOO ; Min Bum KIM ; Min Beom KIM ; Se Hyung KIM ; Young Jin KIM ; Chang Hee KIM ; Sung Il NAM ; Seog Kyun MUN ; Ga Young PARK ; Sang Yoo PARK ; Shi Nae PARK ; Chang Hoon BAE ; Sung Hyun BOO ; Myung Whan SUH ; Jae Hyun SEO ; Eun Jin SON ; Jae Jun SONG ; Jae Jin SONG ; Joong Wook SHIN ; Dae Bo SHIM ; Seong Ki AHN ; Hye Youn YOUM ; Shin Young YOO ; Dong Hee LEE ; Seung Hwan LEE ; Chang Ho LEE ; Hyun Seok LEE ; Hwan Ho LEE ; Hyo Jeong LEE ; Yun Hoon CHOUNG ; Seung Hyo CHOI ; Jee Sun CHOI ; Seok Min HONG ; Sung Kwang HONG
Journal of the Korean Balance Society 2013;12(3):79-92
BACKGROUND AND OBJECTIVES: It is necessary to establish the most efficient diagnostic and therapeutic method for benign paroxysmal positional vertigo (BPPV), which is appropriate for Korean healthcare system. We aimed to evaluate current state of Korean clinician's diagnostic and therapeutic approaches for BPPV. MATERIALS AND METHODS: A 16-item survey was emailed to the members of dizziness department of Otology Research Interest Group in the Korean Otologic Society (n=68). 43 were returned and analyzed. RESULTS: All respondents (100%) used Dix-Hallpike test as a diagnostic tool for vertical canal-BPPV. Supine roll test was used for diagnosing lateral canal BPPV in nearly all the respondents (97.7%). Epley maneuver was chosen as otolith repositioning maneuver (ORM) for posterior canal BPPV in all respondents and barbecue rotation (BBQ) was used for treating lateral canal BPPV with geotropic nystagmus in 95.3% of respondents. Extreme variation was noted for therapeutic approach of lateral canal BPPV with ageotropic nystagmus BBQ, with 4 kinds of ORM and adjunctive measures to liberate otolith from cupula, while BBQ was again the most commonly used ORM (76.7%). CONCLUSION: The development of practical and efficient ORM for lateral canal BPPV with ageotropic nystagmus is necessary.
Surveys and Questionnaires
;
Delivery of Health Care
;
Dizziness
;
Electronic Mail
;
Korea
;
Otolaryngology
;
Otolithic Membrane
;
Public Opinion
;
Vertigo
8.Primary Squamous Cell Carcinoma of the Liver Initially Presenting with Pseudoachalasia.
Mun Ki CHOI ; Gwang Ha KIM ; Geun Am SONG ; Hyung Seok NAM ; Yang Seon YI ; Kang Hee AHN ; Suk KIM ; Joo Yeun KIM ; Do Youn PARK
Gut and Liver 2012;6(2):275-279
Pseudoachalasia secondary to primary squamous cell carcinoma (SCC) of the liver is extremely rare and has not been reported until now. Here, we report a unique case of primary SCC of the liver initially presenting with progressive dysphagia along with short periods of significant weight loss. A 58-year-old man initially presented with progressive dysphagia along with significant weight loss over brief periods of time. The radiographic and manometric findings were consistent with achalasia. Subsequent esophagogastroduodenoscopy revealed a moderately dilated esophagus without evidence of neoplasm or organic obstruction. However, firm resistance was encountered while traversing the esophagogastric junction (EGJ), although no mucosal lesion was identified. Due to the clinical suspicion of the presence of a malignant tumor, endoscopic ultrasonography (EUS) and computed tomography scans of the chest and abdomen were obtained. A huge hepatic mass with irregular margins extending to the EGJ was found. EUS-guided fine-needle aspiration was performed, and the mass was diagnosed as a primary SCC of the liver by immunohistochemical staining.
Abdomen
;
Biopsy, Fine-Needle
;
Carcinoma, Squamous Cell
;
Deglutition Disorders
;
Endoscopy, Digestive System
;
Endosonography
;
Esophageal Achalasia
;
Esophagogastric Junction
;
Esophagus
;
Humans
;
Liver
;
Middle Aged
;
Thorax
;
Weight Loss
9.Predictive Value of Post-Transplant Bone Marrow Plasma Cell Percent in Multiple Myeloma Patients Undergone Autologous Transplantation.
In Hye HWANG ; Joo Seop CHUNG ; Ho Jin SHIN ; Young Jin CHOI ; Moo Kon SONG ; Young Mi SEOL ; Goon Jae CHO ; Bo Gwang CHOI ; Mun Ki CHOI ; Bo Kyung CHOI ; Kang Hee AHN ; Kyung Hwa SHIN ; Hee Sun LEE ; Hyung Seok NAM ; Jong Min HWANG
The Korean Journal of Internal Medicine 2011;26(1):76-81
BACKGROUND/AIMS: Autologous stem cell transplantation (ASCT) has become the treatment of choice for patients with multiple myeloma (MM). Studies have shown that maintenance treatment with interferon-alpha is associated with improved survival rates following ASCT. However, despite these recent advances in regimes, relapses are inevitable; thus, the prediction of relapse following ASCT requires assessment. METHODS: We retrospectively analyzed 39 patients who received ASCT between 2003 and 2008. All patients received chemotherapy with vincristine, adriamycin, and dexamethasone (VAD), and ASCT was performed following high-dose melphalan conditioning therapy. We evaluated the influence of the post-transplant day +14 (D+14) bone marrow plasma cell percent (BMPCp) (> or = 2 vs. < 2%), international scoring system (ISS) stage (II vs. III), response after 3 cycles of VAD therapy (complete response [CR] vs. non-CR), deletion of chromosome 13q (del[13q]) (presence of the abnormality vs. absence), and BMPCp at diagnosis (> or = 50 vs. < 50%) on progression-free survival (PFS) and overall survival (OS). RESULTS: During the median follow-up of 28.0 months, the median PFS and OS were 29.1 and 42.1 months, respectively. By univariate analysis, ISS stage III at diagnosis, BMPCp > or = 50% at diagnosis, CR after 3 cycles of VAD therapy, del (13q) by fluorescence in situ hybridization, and BMPCp > or = 2% at post-transplant D+14 were correlated with PFS and OS. A multivariate analysis revealed that a post-transplant D+14 BMPCp > or = 2% (PFS, hazard ratio [HR] = 4.426, p = 0.008; OS, HR = 3.545, p = 0.038) and CR after 3 cycles of VAD therapy (PFS, HR = 0.072, p = 0.014; OS, HR = 0.055, p = 0.015) were independent prognostic parameters. CONCLUSIONS: Post-transplant D+14 BMPCp is a useful parameter for predicting the outcome for patients with MM receiving ASCT.
Adult
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
;
Bone Marrow/*pathology
;
Combined Modality Therapy
;
Female
;
*Hematopoietic Stem Cell Transplantation
;
Humans
;
Male
;
Middle Aged
;
Multiple Myeloma/mortality/pathology/*therapy
;
Plasma Cells/*pathology
;
Predictive Value of Tests
;
Retrospective Studies
;
Transplantation, Autologous
10.A Case of Benign Biliary Stricture as a Complication of Photodynamic Therapy for Biliary Papillomatosis.
Mun Ki CHOI ; Dong Uk KIM ; Gwang Ha KIM ; Geun Am SONG ; Hyung Seok NAM ; Yang Seon YI ; Kang Hee AHN ; Jung Seop EOM
Korean Journal of Gastrointestinal Endoscopy 2011;42(5):327-333
Biliary papillomatosis is a rare disease with a high risk of recurrence and malignant transformation. Therapeutic options include partial hepatectomy, Whipple's procedure and liver transplantation. If there is no surgical option left due to several reasons, local palliative procedures such as biliary stenting and drainage for the treatment of cholestasis are considered, but tumor growth cannot be influenced. Photodynamic therapy might be a new additional, palliative option for patients with biliary papillomatosis who are not eligible for surgery. Benign biliary stricture is a rare complication of photodynamic therapy. We report here a case of a 63-year-old male who developed benign biliary stricture after photodynamic therapy using the photosensitizer photofrin.
Cholestasis
;
Constriction, Pathologic
;
Dihematoporphyrin Ether
;
Drainage
;
Hepatectomy
;
Humans
;
Liver Transplantation
;
Male
;
Middle Aged
;
Papilloma
;
Photochemotherapy
;
Rare Diseases
;
Recurrence
;
Stents

Result Analysis
Print
Save
E-mail